384 related articles for article (PubMed ID: 16595488)
1. Gluc-Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide.
Meisetschläger G; Poethko T; Stahl A; Wolf I; Scheidhauer K; Schottelius M; Herz M; Wester HJ; Schwaiger M
J Nucl Med; 2006 Apr; 47(4):566-73. PubMed ID: 16595488
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
[TBL] [Abstract][Full Text] [Related]
3. First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography.
Schottelius M; Poethko T; Herz M; Reubi JC; Kessler H; Schwaiger M; Wester HJ
Clin Cancer Res; 2004 Jun; 10(11):3593-606. PubMed ID: 15173065
[TBL] [Abstract][Full Text] [Related]
4. PET/CT with Gluc-Lys-([(18)F]FP)-TOCA: correlation between uptake, size and arterial perfusion in somatostatin receptor positive lesions.
Wieder H; Beer AJ; Poethko T; Meisetschlaeger G; Wester HJ; Rummeny E; Schwaiger M; Stahl AR
Eur J Nucl Med Mol Imaging; 2008 Feb; 35(2):264-71. PubMed ID: 17912524
[TBL] [Abstract][Full Text] [Related]
5. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide.
Stahl A; Meisetschläger G; Schottelius M; Bruus-Jensen K; Wolf I; Scheidhauer K; Schwaiger M
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):45-52. PubMed ID: 16151771
[TBL] [Abstract][Full Text] [Related]
6. Targeting somatostatin receptors: preclinical evaluation of novel 18F-fluoroethyltriazole-Tyr3-octreotate analogs for PET.
Leyton J; Iddon L; Perumal M; Indrevoll B; Glaser M; Robins E; George AJ; Cuthbertson A; Luthra SK; Aboagye EO
J Nucl Med; 2011 Sep; 52(9):1441-8. PubMed ID: 21852355
[TBL] [Abstract][Full Text] [Related]
7. Assessment of tumor volumes in skull base glomus tumors using Gluc-Lys[(18)F]-TOCA positron emission tomography.
Astner ST; Bundschuh RA; Beer AJ; Ziegler SI; Krause BJ; Schwaiger M; Molls M; Grosu AL; Essler M
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1135-40. PubMed ID: 18786781
[TBL] [Abstract][Full Text] [Related]
8. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts.
Vaidyanathan G; Friedman HS; Affleck DJ; Schottelius M; Wester HJ; Zalutsky MR
Clin Cancer Res; 2003 May; 9(5):1868-76. PubMed ID: 12738745
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
[TBL] [Abstract][Full Text] [Related]
10. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
11. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
12. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
[TBL] [Abstract][Full Text] [Related]
13. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
14. Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs.
Poethko T; Schottelius M; Thumshirn G; Hersel U; Herz M; Henriksen G; Kessler H; Schwaiger M; Wester HJ
J Nucl Med; 2004 May; 45(5):892-902. PubMed ID: 15136641
[TBL] [Abstract][Full Text] [Related]
15. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
16. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data.
Hofmann M; Maecke H; Börner R; Weckesser E; Schöffski P; Oei L; Schumacher J; Henze M; Heppeler A; Meyer J; Knapp H
Eur J Nucl Med; 2001 Dec; 28(12):1751-7. PubMed ID: 11734911
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.
Krenning EP; Bakker WH; Kooij PP; Breeman WA; Oei HY; de Jong M; Reubi JC; Visser TJ; Bruns C; Kwekkeboom DJ
J Nucl Med; 1992 May; 33(5):652-8. PubMed ID: 1349039
[TBL] [Abstract][Full Text] [Related]
19. Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
Müssig K; Oksüz MO; Dudziak K; Ueberberg B; Wehrmann M; Horger M; Schulz S; Häring HU; Pfannenberg C; Bares R; Gallwitz B; Petersenn S
Horm Metab Res; 2010 Jul; 42(8):599-606. PubMed ID: 20422506
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
